US Pharma MarketingVerdiva cans mid-stage obesity trial of GLP-1 pill, citing
Verdiva Bio ends a Phase 2 switching trial of its weekly oral GLP-1 ecnoglutide after enrolling 8 patients, as EVOLVE-2 data remain unreleased. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
Verdiva Bio, one of the best-funded private biotechs seeking to get into the lucrative obesity drug market, has terminated one of the Phase 2 trials of its lead asset, a spokesperson ...
Source: Endpoints News